TY  - JOUR
AU  - Pal, Sumanta K
AU  - Somford, Diederik M
AU  - Grivas, Petros
AU  - Sridhar, Srikala S
AU  - Gupta, Shilpa
AU  - Bellmunt, Joaquim
AU  - Sonpavde, Guru
AU  - Fleming, Mark T
AU  - Lerner, Seth P
AU  - Loriot, Yohann
AU  - Hoffman-Censits, Jean
AU  - Valderrama, Begoña P
AU  - Andresen, Corina
AU  - Schnabel, Marco J
AU  - Cole, Suzanne
AU  - Daneshmand, Siamak
PY  - 2022
DO  - 10.2217/fon-2021-1629
UR  - http://hdl.handle.net/10668/20492
T2  - Future oncology (London, England)
AB  - PROOF 302 is an ongoing randomized, double-blind, placebo-controlled, adjuvant phase III trial (NCT04197986) in approximately 218 patients from 120 centers worldwide. Eligibility criteria include post-surgical high-risk muscle-invasive upper tract...
LA  - en
KW  - FGFR inhibitor
KW  - FGFR3
KW  - PROOF 302
KW  - adjuvant cisplatin-based chemotherapy
KW  - adjuvant therapy
KW  - cisplatin-therapy refusal
KW  - fusions or rearrangements
KW  - infigratinib
KW  - muscle-invasive urothelial carcinoma
KW  - mutations
KW  - neoadjuvant cisplatin-based chemotherapy
KW  - phase III
KW  - upper tract urothelial carcinoma
KW  - urothelial bladder carcinoma
KW  - urothelial carcinoma
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Carcinoma, Transitional Cell
KW  - Chemotherapy, Adjuvant
KW  - Humans
KW  - Phenylurea Compounds
KW  - Pyrimidines
KW  - Randomized Controlled Trials as Topic
KW  - Receptor, Fibroblast Growth Factor, Type 3
KW  - Urinary Bladder Neoplasms
TI  - Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial.
TY  - research article
VL  - 18
ER  -